# US 9,040,573 B2 · Anti-fungal agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,573 B2
- Document ID: US9040573B2
- Status: Granted
- Kind: B2
- Application number: 13/995,820
- Filed: 2012-09-25
- Published: 2014-05-22
- Granted: 2015-05-26
- Earliest claimed: 2011-09-26
- Assignees: Nihon Nohyaku Co., Ltd.
- Applicants: Hiroyasu Koga; Yasuko Nanjoh; Ryoji Tsuboi
- Inventors: Hiroyasu Koga; Yasuko Nanjoh; Ryoji Tsuboi
- Web page: https://patentgrep.com/patent/US9040573B2

## CPC

- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/02: for disorders of the vagina
- A61P 17/00: Drugs for dermatological disorders
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 31/10: Antimycotics
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

An antifungal agent against a fungus of the genus Scytalidium (Scytalidium—dimidiatum, Scytalidium—hyalinum etc.), preferably an antifungal agent for superficial mycosis caused by a fungus of the genus Scytalidium as a pathogenic fungus, which contains luliconazole or a pharmaceutically acceptable salt thereof and/or lanoconazole or a pharmaceutically acceptable salt thereof as active ingredient(s).

## Claims

### Claim 1

A method of treating mycosis caused by a fungus of the genus Scytalidium as a pathogenic fungus, comprising administering an effective amount of luliconazole or a pharmaceutically acceptable salt thereof and/or lanoconazole or a pharmaceutically acceptable salt thereof to a subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the mycosis is superficial mycosis.

### Claim 3

A method of treating complex mycosis caused by
(1) a fungus of the genus Scytalidium and
(2) one or more fungi selected from the group consisting of a fungus of the genus Candida, a fungus of the genus Cryptococcus, a fungus of the genus Aspergillus, a fungus of the genus Trichophyton, a fungus of the genus Coccidioides, a fungus of the Zygomycota, a fungus of the genus Trichosporon, a fungus of the genus Microsporon, a fungus of the genus Scopulariopsis, a fungus of the genus Fusarium, a fungus of the genus Alternaria, and a fungus of the genus Acremonium,
as pathogenic fungi,
which comprises administering an effective amount of luliconazole or a pharmaceutically acceptable salt thereof and/or lanoconazole or a pharmaceutically acceptable salt thereof to a subject.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the complex mycosis is superficial mycosis.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the mycosis is selected from superficial mycosis, subcutaneous mycosis, deep mycosis, mycetoma, and fungemia.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the superficial mycosis is a mycosis developed by infection, with the pathogen, of the skin of leg, body and/or head, nail, eye, ear, mouth cavity, nasal cavity, respiratory organ, urinary tract, and/or vagina.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the fungus of the genus Scytalidium is Scytalidium dimidiatum and/or Scytalidium hyalinum.

### Claim 8 (depends on 3)

The method according to claim 3, wherein the complex mycosis is selected from superficial mycosis, subcutaneous mycosis, deep mycosis, mycetoma, and fungemia.

### Claim 9 (depends on 4)

The method according to claim 4, wherein the superficial mycosis is a mycosis developed by infection, with the pathogen, of the skin of leg, body and/or head, nail, eye, ear, mouth cavity, nasal cavity, respiratory organ, urinary tract, and/or vagina.

### Claim 10 (depends on 3)

The method according to claim 3, wherein the fungus of the genus Scytalidium is Scytalidium dimidiatum and/or Scytalidium hyalinum.